Evaluation of Response to Two Schedules of Capecitabine in Patients With Metastatic Breast Cancer (CAP7/7)

The purpose of this study is to compare the efficacy of a novel schedule of an oral anticancer drug, capecitabine, in patients with metastatic breast cancer.

Mathematical models have predicted that 7 days of capecitabine followed by 7 days of rest is an optimal dosing schedule for this drug and previous studies done al Memorial Sloan Kettering Cancer Center support the tolerability of this scheme.

This definitive, randomized trial comparing the efficacy of the new dosage with the conventional dosing schedule in patients with metastatic breast cancer is necessary and we hypothesize it will be superior in terms of efficacy.

Dosing schedules based on mathematical predictions for optimal drug delivery based on efficacy rather than toxicity could facilitate more rapid and economical drug development. This trial is a proof of principle trial of the highest priority.

Study Overview

• Status: Unknown
• Conditions: Breast Cancer
• Intervention / Treatment: Drug: Capecitabine

• Study Type: Interventional
• Enrollment (Anticipated): 350
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Daniel Campos, MD; Phone Number: +5491144204242; Email: dcampos@slacom.org

Study Locations

• Argentina
  • Buenos Aires, Argentina, 1120
    • Recruiting
    • SLACOM

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• 1 Subject Inclusion Criteria

  • Informed consent has been obtained.
  • Metastatic breast cancer.
  • Measurable or non-measurable disease per RECIST criteria.
  • Pathologic confirmation of breast cancer.
  • No limit to the number of prior chemotherapy regimens permitted for metastatic disease.
  • At least 3 weeks since prior chemotherapy. Patients should have recovered from all acute toxicity from such therapy (excluding alopecia).
  • Age ≥18.
  • ECOG 0-2

  • Absolute Neutrophil Count (ANC )≥1.0; hemoglobin ≥9, platelets

    ≥75.000

  • AST, ALT and Alkaline phosphatase <2.5x upper limit of normal (or <5x upper limit of normal in the case of liver metastases). Total bilirubin <1.5x upper limit of normal.
  • Estimated creatinine clearance >50ml/min.
  • If female of childbearing potential, pregnancy test is negative and the patient agrees to use an effective method to avoid pregnancy during the study.

Exclusion Criteria:

• HER2 over-expression and/or amplification as determined by immunohistochemistry (3+) or FISH (>2.0).

  • No prior fluoropyrimidine in the metastatic setting. Adjuvant fluoropyrimidine is permitted if >12 months have elapsed since treatment.
  • No restriction for prior hormonal therapy.
  • GI malabsorption syndrome which could impair oral drug absorption.
  • Concurrent use of warfarin is discouraged as drug interactions may make management of INR more difficult.
  • Central nervous system metastases are permitted if previously treated or clinically stable for at least 3 months.
  • Pregnant or nursing patients.
  • Life expectancy <3 months.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Arm A: Capecitabine 2,000 mg (flat dose); Arm A: Capecitabine 2,000 mg (flat dose), orally, twice daily for 7 days followed by a 7 day rest (7-7) (4-week cycle length ).	Drug: Capecitabine; Two dosages comparison; Other Names: Xeloda
Active Comparator: Arm B: Capecitabine 1,000 mg/m2 twice daily for 14 day; Arm B: Capecitabine 1,000 mg/m2, orally, twice daily for 14 days followed by a 7 day rest (14-7) (3-week cycle length ). The control arm dose of capecitabine has been reduced from the US Food and Drug Administration approved dose of 1,250 mg/m2, orally, twice daily due to common clinical practice.	Drug: Capecitabine; Two dosages comparison; Other Names: Xeloda

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Progress Free Survival (PFS)	The primary endpoint of this study is PFS, defined as the time from treatment start to progression or last date of follow-up. PFS will be estimated using Kaplan-Meier methods. This will be an intention to treat analysis. The Log-rank test will be used to test whether PFS is different for the two capecitabine schedules. It is hypothesized that the 7-7 schedule of capecitabine will have superior efficacy.	24 month

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with toxicity.	Secondary Objectives: To assess and compare tolerability of the two capecitabine schedules in terms of selected hematologic and non-hematologic toxicities.; To compare the rates of grade 3 or greater diarrhea, nausea and vomiting between the two schedules.	24 month
Number of patients with treatment delays.		24 month
Number of patients with dose reduction.		24 month
Number of patients with study withdrawal.		24 month

Collaborators and Investigators

• Sponsor: Latin American & Caribbean Society of Medical Oncology
• Collaborators: Breast Cancer Research Foundation
• Investigators: Study Chair: Eduardo Cazap, MD,PhD, Latin American & Caribbean Society of Medical Oncology; Study Chair: Tiffany Traina, MD, MSKCC

Study record dates

Study Major Dates

• Study Start: August 1, 2013
• Primary Completion (Anticipated): December 1, 2018
• Study Completion (Anticipated): March 1, 2019

Study Registration Dates

• First Submitted: January 3, 2014
• First Submitted That Met QC Criteria: January 3, 2014
• First Posted (Estimate): January 7, 2014

Study Record Updates

• Last Update Posted (Actual): September 7, 2018
• Last Update Submitted That Met QC Criteria: September 6, 2018
• Last Verified: September 1, 2018

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms; Molecular Mechanisms of Pharmacological Action; Antimetabolites, Antineoplastic; Antimetabolites; Antineoplastic Agents; Capecitabine
• Other Study ID Numbers: SLACOM Cap 7/7

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED